Objectives: The aims were to study if efflux and down-regulation of porins contribute to cefuroxime resistance in Klebsiella pneumoniae and to co-resistance to unrelated antibiotics.
Introduction
Acknowledged cefuroxime resistance mechanisms in Klebsiella pneumoniae are production of extended-spectrum b-lactamases (ESBLs) and down-regulation of porins, especially OmpK35. 1, 2 In Escherichia coli, active efflux has been shown as a possible cause of cefuroxime resistance. 3 As in E. coli, the efflux pump AcrAB seems to be important for efflux-mediated resistance in K. pneumoniae. 4 Mutations in the local regulator gene acrR have been shown to be associated with increased expression of acrA in K. pneumoniae. 4 RamA, MarA and SoxS are global regulatory proteins involved in multidrug resistance (MDR). 4, 5 RamA is a transcriptional activator in K. pneumoniae involved in the regulation of acrAB expression and maybe also in the expression of other efflux pumps and porins. 4 -6 MarA and SoxS cause decreased porin expression and increased efflux pump expression in different species of Enterobacteriaceae. 4 In this study, cefuroxime-resistant strains of K. pneumoniae were examined for the putative resistance mechanisms efflux, porin loss and ESBL production.
Materials and methods

Bacterial strains
All clinical blood culture isolates of K. pneumoniae from 2004 to 2006 (from the clinical laboratory at Karolinska University Hospital, Solna, Stockholm) that were cefuroxime-non-susceptible but cefotaxime-susceptible were examined (n ¼ 10). K. pneumoniae ATCC 25955 was used as a control strain.
Selection of multiply antibiotic-resistant (MAR) laboratory strain K. pneumoniae ATCC 25955 was grown on Iso-Sensitest agar (ISA) (Oxoid, Basingstoke, UK) containing chloramphenicol in increasing concentrations (3-4 cycles), and a strain with chloramphenicol MIC . 256 mg/L was selected. It quite easily reverted phenotypically to the original strain and was therefore grown in media containing 64 mg/L chloramphenicol. Similar methods have been used before. 7 
Antimicrobial susceptibility testing
MICs of cefuroxime, cefotaxime, ceftazidime, chloramphenicol, tigecycline, tetracycline, ciprofloxacin and trimethoprim/sulfamethoxazole were determined by Etest (Biodisk, Solna, Sweden) (www.srga.org). Susceptibility to nalidixic acid (30 mg discs) was determined by the disc diffusion method (Oxoid), (www.srga.org). Screening for ESBLs was performed using Etest ESBL (cefotaxime/ cefotaxime þ clavulanic acid and ceftazidime/ceftazidime þ clavulanic acid) (Biodisk) (www.srga.org). MICs and inhibition zones, respectively, of the above-mentioned antibiotics were also determined on ISA plates containing the efflux pump inhibitor phenylalanine arginine b-naphthylamide (PAbN) (Sigma-Aldrich, St Louis, MO, USA) at 40 mg/L and for cefuroxime also on ISA plates containing clavulanic acid (Sigma-Aldrich) at 2 mg/L.
Real-time RT -PCR for quantification of mRNA encoded by acrA, ompK35, ramA, marA and soxS Real-time RT-PCR was used to analyse the mRNA (transcription) levels of the genes acrA, ompK35, ramA, marA and soxS. As a reference, gene rrsE was used for normalizing the transcription levels of target genes. 6 The method has previously been described for Pseudomonas aeruginosa 8 and was used with some minor modifications. Total RNA was extracted (High Pure RNA Isolation Kit, Roche, Mannheim, Germany) and synthesis of cDNA from 20 ng of extracted RNA for each reaction was performed using the 1st strand cDNA synthesis kit for RT-PCR (Roche). With the Rotor-Gene 3000 real-time PCR apparatus (Corbett Research, Morlake, Australia) using SYBR Green (Qiagen, Hilden, Germany) for DNA detection and specific primers (Cybergene, Huddinge, Sweden), real-time PCR (40 cycles, 20 s each per cycle of 958, 528 and 728) was performed to quantify cDNA. Primers used (5 0 -3 0 ) for acrA were ATGTGACGATAAACCGGCTC and CTGGCAGTTCGG TGGTTATT, for ompK35 GAAGGTTCCCAGACCACAAA and ACGGCCATAGTCGAATGAAC, for ramA 6 GCATCAACCGCTGC GTATT and CGTTGCAGATGCCATTTCG, for marA GAATGG CCGGTCTCTTTCTT and CCTGTCGCTGGAAAAAGTGT, for soxS GCAGGCGGCGCTGGCGAATA and AGTCGCCAGAAA GTCAGGAT and for rrsE 6 TTGACGTTACCCGCAGAAGAA and GCTTGCACCCTCCGTATTACC. The specificity of the generated product was tested by melting-point analysis. Cycle threshold (CT) values of the target genes were directly compared with the CT values of the reference gene, rendering the normalized expression (transcription) value. Amplification was performed in triplicate from three different cDNA preparations. The mean of the normalized expression (transcription) values was calculated for acrA, ramA, marA, soxS and ompK35 for each strain, using the Q-gene software. 8 Statistical analysis was performed with t-test for independent samples.
DNA sequence analysis
The acrR gene was amplified using a forward primer located upstream (CGTAACCTCTGTAAAGTCAT) and a reverse primer at the end of the gene (GCTGACAAGCTCTCCGGGC) (5 0 -3 0 , Cybergene). AmpliTaqGold (Applied Biosystems, Stockholm, Sweden) was used for the PCR, and the cycling programme comprised 10 min at 958C, followed by 30 cycles of 45 s at 948C, 45 s at 528C and 2 min at 728C, with a final extension for 10 min at 728C. PCR templates were purified with the Jetquick Spin Column Kit (Genomed; Saveen Werner AB, Malmoe, Sweden). DNA sequencing of PCR products was performed with the dideoxy chaintermination method. The amplification primers were used for the sequence reactions along with an additional internal forward primer (AAGTGTGAGTTCGTCGGTGA) (5 0 -3 0 , Cybergene). Sequence reactions were performed using an ABI Prism Big Dye Terminator Cycle Sequencing kit v.3.1 (Applied Biosystems) according to the manufacturer's instructions. Sequence analysis was performed on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems) using Seqscape software v.2.5.0 (Applied Biosystems).
PhP typing
In order to confirm that the clinical isolates did not represent one clone of K. pneumoniae with the same antibiotic susceptibility pattern, a semi-automated system for biochemical fingerprinting (the PhenePlate or PhP system) was used for the clinical isolates (PhPlate AB, Stockholm Sweden). 9 The correlation coefficient (r) between each pair of isolates was calculated and isolates with r 0.97 were considered to belong to the same PhP type, and hence to be potentially clonally related. 9 Only two of the clinical isolates (KP-7 and KP-10) were found to belong to the same PhP-type.
Results and discussion
Antibiotic susceptibility
MICs and inhibition zones without and with PAbN are shown in Table 1 . The MAR laboratory strain and the clinical isolates showed similar antibiograms, with non-susceptibility to cefuroxime, chloramphenicol, nalidixic acid and tigecycline. However, while the clinical isolates were phenotypically stable, the MAR laboratory strain was unstable, suggesting that the strain was phenotypically adapted to high antibiotic concentrations. Several isolates showed decreased susceptibility to ceftazidime and though they were cefotaxime-susceptible, MICs were higher than for the ATCC strain and for the wild-type population (www.eucast.org). All clinical isolates were ESBL-negative and clavulanic acid did not decrease the cefuroxime MIC significantly (4-fold) in any of the strains, which makes overexpression of SHV-1 unlikely (data not shown). PAbN increased susceptibility significantly (4-fold MIC decrease or 5 mm increase in inhibition zone diameter) to chloramphenicol, nalidixic acid, tigecycline and trimethoprim/sulfamethoxazole in the MAR laboratory strain and in most clinical isolates, while cephalosporin susceptibility was not affected significantly. This suggests that the decreased susceptibility to chloramphenicol, nalidixic acid and tigecycline is at least partly explained by efflux, but that another mechanism ( probably lack of ompK35) is the cause of the cefuroxime resistance. K. pneumoniae strains with a similar MDR pattern with resistance to nalidixic acid, chloramphenicol and trimethoprim have been described before, but cefuroxime susceptibility was not determined in these studies. 6, 10 Proposed mechanisms explaining this phenotype pattern have been down-regulation of porins and increased efflux due to increased expression of the AcrAB efflux pump. 6, 10 In this study we found that this MDR phenotype is also associated with cefuroxime resistance and that all clinical isolates in this study, selected primarily because they were cefuroxime-nonsusceptible but cefotaxime-susceptible, were also non-susceptible to chloramphenicol, tigecycline and nalidixic acid. In a study of antibiotic cross-resistance in K. pneumoniae, 91% of isolates with decreased cefuroxime susceptibility were also chloramphenicolnon-susceptible, compared with 7% of the cefuroxime-susceptible isolates.
11 This provides further evidence for the existence of co-resistance between these chemically unrelated antimicrobial agents.
Transcription of acrA, ompK35, ramA, marA and soxS and acrR sequencing
The relative transcription levels (compared with the ATCC strain) for each strain for the examined genes are shown in Table 2 . All strains had increased acrA transcription levels and decreased ompK35 transcription levels. Further, all strains except one (KP-4) had increased ramA transcription levels. Four of the clinical isolates and the MAR laboratory strain had significantly increased transcription levels of marA. For soxS, only the MAR laboratory strain had increased transcription levels. Thus, ramA seems to be the most important transcriptional activator, rendering the MDR phenotype in the clinical isolates and the laboratory strain, though marA and soxS might also be of importance in the laboratory strain. Overexpression of ramA (but not of marA and soxS) has previously been associated with increased acrAB expression in clinical isolates of K. pneumoniae. 4 The sequences of the acrR regulatory gene were compared with a published GenBank sequence (NC_009648). Except for some silent mutations, only one single amino acid change of uncertain relevance was found: isolate KP-3 featuring a Glu190Lys change (Table 2) .
Conclusions
Current evidence suggests that increased expression of ramA, resulting in increased acrAB expression and decreased ompK35 expression contributes to decreased susceptibility to several unrelated antibiotics: cefuroxime, tigecycline, chloramphenicol, nalidixic acid and, in most isolates, trimethoprim/sulfamethoxazole. The cefuroxime resistance was not reversed by the efflux pump inhibitor PAbN, implying loss of OmpK35 as the probable cause of cefuroxime resistance, while efflux of the AcrAB pump at least partially explains the non-susceptibility to tigecycline, chloramphenicol, nalidixic acid and trimethoprim/sulfamethoxazole. The finding of this MDR profile in multiple blood culture isolates of K. pneumoniae, all of them employing the same mechanisms of resistance, underscores the clinical importance of this phenotype.
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